SCHEMBL5152247

SCHEMBL5152247

COc1cccc(-n2c(-c3cccc(C#N)c3)nc3cnc(NCCc4ccccc4F)nc32)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 12/20 0.48
MEN1 O00255 9/20 0.48
KMT2A Q03164 9/20 0.48
CASP1 P29466 4/20 0.48
CASP7 P55210 3/20 0.48
CYP3A4 P08684 10/20 0.46
ADORA2A P29274 8/20 0.46
ADORA1 P30542 8/20 0.46
BRCA1 P38398 1/20 0.46
CYP1A2 P05177 10/20 0.43
CYP2D6 P10635 6/20 0.43
ALDH1A1 P00352 6/20 0.43
HIF1A Q16665 4/20 0.43
HSD17B10 Q99714 3/20 0.43
HPGD P15428 2/20 0.43
GLA P06280 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP2C19 P33261 6/20 0.42
CLK4 Q9HAZ1 6/20 0.42
CYP2C9 P11712 5/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5153465 0.90 ADORA2A (0.48) USP2MEN1KMT2ACASP1CASP7
SCHEMBL8241181 0.88 ADORA2A (0.47) USP2MEN1KMT2ACASP1CASP7
SCHEMBL5156664 0.85 ADORA2A (0.55) USP2MEN1KMT2ACASP1CASP7
SCHEMBL5153092 0.82 ADORA2A (0.47) USP2MEN1KMT2ACYP3A4ADORA2A
SCHEMBL14407605 0.81 CYP1A2 (0.50) USP2MEN1KMT2ACASP1CASP7
SCHEMBL5152257 0.80 USP2 (0.51) USP2MEN1KMT2ACASP1CASP7
SCHEMBL4507899 0.74 ADORA2A (0.53) USP2CYP3A4ADORA2AADORA1CYP1A2
SCHEMBL5155796 0.74 CYP1A2 (0.49) USP2MEN1KMT2ACASP1CASP7
SCHEMBL5152081 0.73 CYP1A2 (0.50) USP2MEN1KMT2ACASP1CASP7
SCHEMBL5332245 0.73 ADORA2A (0.69) ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225304-A1 AMINOPURINE DERIVATIVES FOR TREATING NEURODEGENERATIVE DISEASES PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2007-09-27 US disclosed
US-20070225304-A1 AMINOPURINE DERIVATIVES FOR TREATING NEURODEGENERATIVE DISEASES PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2007-09-27 US disclosed
US-20070225304-A1 AMINOPURINE DERIVATIVES FOR TREATING NEURODEGENERATIVE DISEASES PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2007-09-27 US disclosed
WO-2007030438-A2 AMINOPURINE DERIVATIVES FOR TREATING NEURODEGENERATIVE DISEASES PHARMACOPEIA, INC. (US) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225304-A1 AMINOPURINE DERIVATIVES FOR TREATING NEURODEGENERATIVE DISEASES TPMT, ADORA2A, ENTPD5 USP2 2651/4885MEN1 4507/4885KMT2A 1541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.